INCYTE
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Delaware, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1801 Augustine Cut Off, Wilmington, Dela...Phone Number
(302) 498-6700Website
www.incyte.comRevenue
$5.4 BillionStock Symbol
INCYIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
1
1
About INCYTE
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.Explore more
INCYTE Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INCYTE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when INCYTE launches new products
Congratulate Masked Content for being promoted to Masked Content at INCYTE
INCYTE, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once INCYTE has new funding data
Check if INCYTE has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if INCYTE had a recent Job posting/layoffs
Check out if INCYTE is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on INCYTE recently announced quarterly report
Recommended Actions
Find VP level buyers at INCYTE
Find 2 more new buyers
Compare Similar Companies to INCYTE
Compare insights from companies similar to INCYTE, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$827.1M
501-1,000
Public
$2.5B
1998
QN
Quintus NgumahVice President, Clinical Development & Chief Marketing Officer, Cos To The
Company Profile Activity
Activity Insights
INCYTE is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INCYTE is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INCYTE.
INCYTE Tech Stack
A closer look at the technologies used by INCYTE
See more technologies
Most Recent Scoops
Earnings
INCYTE has reported Jakafi net sales of $817 million for Q2 2026, an increase of 7% year over year, driven by a 9% increase in prescription demand across all indications myelofibrosis, polycythemia vera, and graft-versus-host disease with polycythemia vera being the largest growth driver.
Earnings, Pharmaceuticals, Finance
Project
INCYTE has announced that it remains on track to report top-line results from its registrational Phase III program evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa by year-end 2026, which, if positive, could support the first topical therapy specifically developed for patients with hidradenitis suppurativa.
Pharmaceuticals
Earnings
INCYTE has reported total GAAP operating expenses of $976 million for Q2 2026, an increase of 42% compared to the prior year; excluding a favorable $242 million Novartis settlement adjustment recorded in Q2 2025, total operating expenses grew 5% year over year.
Earnings, Accounting, Financial Reporting, Finance
Earnings
INCYTE has raised its full-year 2026 total net sales guidance to $5.13 billion to $5.26 billion.
Earnings, Forecasting, Finance
Earnings
Earnings, Finance
INCYTE News & Media
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Incyte Corporation (INCY) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDTCompany ParticipantsAlexis Smith - VP & Head of Investor RelationsWilliam Meury...Incyte Q2 Earnings Call Highlights
Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA. Excluding the $246 million one-time bHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today...Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INCYTE
Sign Up For FreeTo access detailed company insights
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome... Read More
